HIV drug resistance and optimization of antiviral treatment in resource-poor countries;Résistance du VIH aux antirétroviraux: Conséquences pour les pays à faibles revenus

Medecine/Sciences

Volumn 20, Issue 10, 2004, Pages 882-886

  Doualla Bell, Florence ^a   Turner, Dan ^a   Loemba, Hugues ^a   Petrella, Marco ^a   Brenner, Bluma ^a   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CORRELATION ANALYSIS; DNA POLYMORPHISM; GENE MUTATION; GENOTYPE; HEALTH CARE UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PROGNOSIS; REVIEW; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 6344291439     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/20042010882     Document Type: Review

References (42)

1. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy for HIV infection in adults. JAMA 2000; 283: 381-90.
2. Gayle HD, Hill GL. Global impact of human immunodeficiency virus and AIDS. Clin Microbiol Rev 2001; 14: 327-35.
3. Cock KM, Weiss HA. The global epidemiology of HIV/AIDS. Trop Med Int Health 2000; 5: A3-9.
4. Cohen J. Confronting the limits of success. Science 2002; 296: 2320-4.
5. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA panel. JAMA 2002; 288: 222-35.
6. Furman PA, Fyfe JA, St Clair MH, et al. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interactions of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986; 83: 8333-7.
7. Hart GJ, Orr DC, Penn CR, et al. Effects of 2′-deoxy-3′- thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta and gamma. Antimicrob Agents Chemother 1992; 37: 918-20.
8. Spence RA, Kati WM, Anderson KS, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Science 1995; 267: 988-92.
9. Gu Z, Quan Y, Li Z, et al. Effects of non-nucleosides inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assay. J Biol Chem 1995; 270: 31046-51.
10. Boden D, Markowitz M. Resistance to human immunodeficiency type 1 protease inhibitors. Antimicrob Agents Chemother 1998; 42: 2775-83.
11. Quiros-Roldan E, Signorini S, Castelli F, et al. Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy. J Clin Lab Anal 2001; 15: 43-6.
12. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV cohort study. AIDS 1999; 13: F17-21.
13. Johnson VA, Brun-Vésinet F, Clotet B, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11: 215-21.
14. nd ed. Dordrech: Kluwer Press 2002: 345-54.
15. Brenner BG, Wainberg MA. The role of antiretrovirals and drug resistance in vertical transmission. Ann NY Acad Sci 2000; 918: 9-15.
16. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72: 2422-8.
17. Kuritzkes D. Progress in drug-resistance testing in the management of antiretroviral therapy. PRN Notebook 1999; 4: 14-8.
18. Larder BA, Kemp SD, Hertogs K, et al. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (virtual phenotype). Antiviral Ther 2000; 5: 49 (abstract).
19. Sheldon JG, Condra JH. Genotypic analysis methods for detection of drug resistance mutations in the HIV-1 proteinase and reverse transcriptase genes. Antiviral Ther 1999; 4: 135-42.
20. ONUSIDA/OMS 2003. Le point sur l'épidémie de sida.1-39. http://www.unaids.org/
21. World Health Organization. Safe and effective use of antiretroviral treatments in adults. With particular references to resource limited setting. Geneva: WHO, 2000: 1-21. http://whqlibdoc.who.int/hq/2000/WHO_HSI_2000.04.pdf
22. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group 0 isolates to antiretroviral agents: in vitro phenotypic and genotypic analysis. J Virol 1997; 71: 8893-8.
23. Loemba H, Brenner B, Parniak MA, et al. Genotypic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against non-nucleoside inhibitors of RT. Antimicrob Agents Chemother 2002; 46: 2087-94.
24. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Gene 2001; 23: 193-202.
25. Loemba H, Brenner B, Parniak MA, et al. Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. Antiviral Res 2002; 56: 129-42.
26. Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003; 17: 1-5.
27. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevirapine resistance mutations in women with subtype A Vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Def Syndr 2004; 35: 126-30.
28. nd IAS conference on HIV pathogenesis and treatment, 2003: 685 (abstract).
29. Weidle PJ, Downing R, Sozi C, et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative-Uganda. AIDS 2003; 17: 539-48.
30. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS 2003; 17: 55-15.
31. Laniece I, Ciss M, Desclaux A, et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS 2003; 17: S103-8.
32. th Conference on retroviruses and opportunistic infections, 2000: 73 (abstract).
33. nd ed. Dordrech: Kluwer Press, 2002: 322-33.
34. Liechty CA, Bansberg DR. Doubts about DOT: antiretroviral therapy for resource-poor countries. AIDS 2003; 17: 1383-7.
35. Farmer P, Leandre F, Mukherjee JS, et al. Community-based approaches to HIV treatment in resource-poor settings. Lancet 2001; 358: 404-9.
36. Hirsch MS, Brun-Vézinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1. Recommendations of an international AIDS society-USA panel. Clin Infect Dis 2003; 37: 113-28.
37. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353: 2195-9.
38. Baxter JD, Mayers D, Wentworth DN, et al. Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Antiviral Ther 1999; 4: 61 (abstract).
39. Ravela J, Betts BJ, Brun-Vezinet F, et al. HIV-1 protease and reverse transcriptase patterns responsible of discordances between genotypic drug resistance interpretation algorithms. J AIDS 2003; 33: 8-14.
40. Götte M, Wainberg MA. Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase. Drug Resist Updates 2000; 3: 30-8.
41. Guay LA, Musoke P, FlemingT, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354: 795-802.
42. th Conference on retroviruses and opportunistic infections, 2003: 176 (abstract).